Rastilav Bahleda

A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Eric Angevin, Josep Tabernero, Élena Elez et al. · Clinical Cancer Research · 2014 · 198 citations

Kidney Diseases Associated With Anti-Vascular Endothelial Growth Factor (VEGF)

Hassan Izzedine, Bernard Escudier, Catherine Lhommé et al. · Medicine · 2014 · 170 citations · Full text

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

J.C. Soria, Rastilav Bahleda, Bárbara Adamo et al. · Annals of Oncology · 2014 · 169 citations · Full text

Oncology, Phase I/iia Study, Pharmacology +6

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti et al. · Clinical Cancer Research · 2019 · 162 citations · Full text

First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

Maria Martinez‐García, Udai Banerji, Joan Albanell et al. · Clinical Cancer Research · 2012 · 151 citations